MARKET WIRETradingView • 1d ago
Cue Biopharma, Inc. Estimates – NASDAQ:CUETradingView report covering Cue Biopharma Inc. (CUE) market action, institutional positioning, and fundamental catalysts.
Why CUE Stock dropped -6.95% Today — RQD Quant Desk Flash
$19.42 -6.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $19.14
Cue Biopharma Inc. (CUE) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $151.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CUE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CUE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Cue Biopharma Inc. (NASDAQ: CUE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $19.42 (-6.95% 1D, market cap $151.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CUE compare to PDSB and ALXO in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CUE carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PDSB (PDS Biotechnology Corporation) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $151.2M) and ALXO (ALX Oncology Holdings Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $152.4M). Among the 5-stock peer group, CUE leads on earnings multiple (N/A) while CNTN leads on capital efficiency (-4.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CUE?
▼
Per CUE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001645460), Cue Biopharma Inc. generated $27.5M in revenue (+195.7% YoY), -$26.6M in net income, and -$21.9M in free cash flow against $42.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $19.14 (-1.44%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-13% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CUE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY CUE SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (28% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$24.61-34.7% Next Q
37
Q2 (-2Q)Grade E$16.08+14.7% Next Q
34
Q3 (-1Q)Grade E$18.45+5.3% Next Q
32
CurrentGrade E$19.42-9.8% Hist 90D α
29
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CUE Turnaround Squeeze
While CUE currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($25.46) and Max Pain ($20.39) forces dealer call-delta covering toward $47.77.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CUE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CUE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CUE Stock dropped -6.95% Today — RQD Quant Desk Flash
Cue Biopharma Inc. (CUE) dropped -6.95% to $19.42, trading at 36% of its 52-week range ($4.98 – $45.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 36% of its 52-week range ($4.98 – $45.5) with RSI-14 at 46.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $19.42 (no active unusual options sweep snapshot on file).
- ▸Primary SEC / Cross-Feed Trigger: CUE Exhibits 4.85x True Net Liquidity Elasticity as Fed-TGA-RRP Prints $5,746B
Live CUE Headlines & Catalysts
MARKET WIREInvesting.com Nigeria • 1d ago
Cue Biopharma’s chief legal officer sells $51,724 in stock By Investing.comInvesting.com Nigeria report covering Cue Biopharma Inc. (CUE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Tax withholding prompts a proposed 11,087-share sale by Cue Biopharma (CUE) officer Shao-Lee Lin.Stock Titan report covering Cue Biopharma Inc. (CUE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
B. Riley sets USD 83 target for Cue Biopharma stockad-hoc-news.de report covering Cue Biopharma Inc. (CUE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREValue Research • 1d ago
Cue Biopharma (CUE) Shareholding Pattern – Promoters, FIIs & DIIsValue Research report covering Cue Biopharma Inc. (CUE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A non-discretionary $51.7K share sale at Cue Biopharma (CUE) would cover stock-grant taxes.Stock Titan report covering Cue Biopharma Inc. (CUE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Cue Biopharma (CUE) Slips 2.61% to $18.11 as Shares Pull Back Toward Support - Max Pain Levelhttps://www.siam.in/ report covering Cue Biopharma Inc. (CUE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 21d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market SessionGainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 93.3% to $2.03 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock rose
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CUE)
- ✓Walkthrough of CUE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CUE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -34.94%▼ DESCENDING CHANNEL
2026-11-03O $21.45H $21.45L $19.42C $19.42VOL 60.8K
RES: $39.10SUP: $14.43SMA50: $25.46SMA200: $21.21
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CUE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +195.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on CUE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CUE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CUE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CUE)
Health Care Rank #834 of 1015
⚔️ PDSB vs CUE Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CUE vs. PDSB, ALXO, MGNX, CNTN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Cue Biopharma Inc. (CUE) ranks #834 by composite RQD confidence (29/100, grade E) and #603 by equity capitalization ($151.6M). Within this direct 5-issuer industry benchmark cohort, CUE leads on earnings valuation at N/A trailing P/E, while CNTN leads on capital efficiency and profitability with -4.1% ROIC and — gross margin. PDSB currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with CUE at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CUE
ACTIVE
Cue Biopharma Inc. | E | 29/100 | — | — | -35.0% | -6.95% | $151.6M | Benchmark Subject |
| PDSB PDS Biotechnology Corporation | D | 46/100 | — | — | -35.0% | -4.86% | $151.2M | /pdsb-vs-cue → |
| ALXO ALX Oncology Holdings Inc. | D | 44/100 | — | — | -35.0% | +12.30% | $152.4M | /alxo-vs-cue → |
| MGNX MacroGenics Inc. | E | 24/100 | — | 96.0% | -35.0% | -2.92% | $152.9M | /mgnx-vs-cue → |
| CNTN Canton Strategic Holdings Inc. | E | 33/100 | — | — | -4.1% | +4.62% | $155.4M | /cntn-vs-cue → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001645460 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cue Biopharma Inc. (CUE) reported GAAP revenue of $27.5M (+195.7% vs. FY2024 revenue of $9.3M , and +400.3% cumulative change since FY2023) , GAAP net income of -$26.6M, operating cash flow of -$21.7M, and free cash flow of -$21.9M (+39.9% YoY). On the balance sheet, CUE closed FY2025 with $42.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $27.5M | -$26.6M | -$21.7M | -$21.9M | $42.2M | — |
| FY2024 (FY) | 2024-12-31 | $9.3M | -$40.7M | -$36.3M | -$36.4M | $32.2M | $0 |
| FY2023 (FY) | 2023-12-31 | $5.5M | -$50.7M | -$40.0M | -$40.0M | — | — |
3. CUE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CUE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Cue Biopharma Inc. (NASDAQ: CUE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $19.42 (-6.95% 1D, market cap $151.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
How does CUE compare to PDSB and ALXO in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CUE carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PDSB (PDS Biotechnology Corporation) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $151.2M) and ALXO (ALX Oncology Holdings Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $152.4M). Among the 5-stock peer group, CUE leads on earnings multiple (N/A) while CNTN leads on capital efficiency (-4.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CUE?
Per CUE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001645460), Cue Biopharma Inc. generated $27.5M in revenue (+195.7% YoY), -$26.6M in net income, and -$21.9M in free cash flow against $42.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CUE trading relative to its 50-day, 200-day, and 52-week technical levels?
CUE last traded at $19.42 (-6.95% on volume of 140,973 shares), positioning the stock -23.72% below its 50-day simple moving average ($25.46) and -8.44% below its 200-day simple moving average ($21.21). Across its 52-week range of $4.98 to $45.50, CUE sits at the 35.6% percentile with a 14-day RSI of 46.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($16.99 to $21.85).
ROARABLE RATING BRIEF • RQD 29/100 (E)
✓ SEC XBRL & RQD VERIFIED
CUE — Cue Biopharma Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Cue Biopharma Inc. (CUE) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $19.42 (-6.95% 1D, market capitalization $151.6M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -14.03%.
- Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (4/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Cue Biopharma Inc. Is a NASDAQ-listed issuer in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. The profile does not describe its specific products, customers, or revenue model. The company reported revenue of $27.5M for FY 2025, up from $9.3M in FY 2024 and $5..2B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cue Biopharma Inc. (CUE) reported $27.5M in annual revenue (up from $9.3M in FY2024, +195.7% YoY) and -$26.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($5.5M revenue, -$50.7M net income) through FY2025, CUE scaled operating cash flow to -$21.7M and free cash flow to -$21.9M, backed by $42.2M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -14.03% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $4.98 – $45.50 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the source data.
- Key Question #1: Can CUE sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $27.5M and free cash flow of -$21.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is CUE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
CUE Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Cue Biopharma Inc. (CUE) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 1d ago
Cue Biopharma, Inc. Estimates – NASDAQ:CUE TradingView report covering Cue Biopharma Inc. (CUE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com Nigeria • 1d ago
Cue Biopharma’s chief legal officer sells $51,724 in stock By Investing.com Investing.com Nigeria report covering Cue Biopharma Inc. (CUE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Tax withholding prompts a proposed 11,087-share sale by Cue Biopharma (CUE) officer Shao-Lee Lin. Stock Titan report covering Cue Biopharma Inc. (CUE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
B. Riley sets USD 83 target for Cue Biopharma stock ad-hoc-news.de report covering Cue Biopharma Inc. (CUE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Value Research • 1d ago
Cue Biopharma (CUE) Shareholding Pattern – Promoters, FIIs & DIIs Value Research report covering Cue Biopharma Inc. (CUE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A non-discretionary $51.7K share sale at Cue Biopharma (CUE) would cover stock-grant taxes. Stock Titan report covering Cue Biopharma Inc. (CUE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Cue Biopharma (CUE) Slips 2.61% to $18.11 as Shares Pull Back Toward Support - Max Pain Level https://www.siam.in/ report covering Cue Biopharma Inc. (CUE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 21d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 93.3% to $2.03 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock rose
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CUE Bull vs. Bear Conversation Board — What's Your Call at $19.42?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CUE 🐻 33% BEARISH CONVICTION
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH
🎯 Target: $26.92 (+29.0%)
📌 Pinned Debate Reported revenue grew from $5.5M in FY 2023 to $27.5M in FY 2025 while operating losses narrowed from -$52.1M to -$26.6M.
The street is overcomplicating Cue Biopharma Inc. (CUE). Reported revenue grew from $5.5M in FY 2023 to $27.5M in FY 2025 while operating losses narrowed from -$52.1M to -$26.6M.. With an RQD score of 29/100 (E) and Forensic Balance Sheet at 8/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $22.54.
SectorRotator 🐂 BULL
@AlphaFlow_Cap Agree on the RQD 29/100 quality, though with 1.0 beta I'm scaling in with half-size at $20.87 and keeping dry powder in case we test $19.41.
BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH
🎯 Target: $16.70 (-20.0%)
Spot @ $20.87 ROIC of -35%, FCF yield of -14.03%, and insider conviction scoring 3/20 signal ongoing cash burn and weak insider confidence.
ROIC of -35%, FCF yield of -14.03%, and insider conviction scoring 3/20 signal ongoing cash burn and weak insider confidence.. Look at the math on CUE: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $18.37 before getting long.